This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
Feb 28, 2033formulationUS 10603384
Feb 28, 2033formulationUS 10603384
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y
Jan 18, 2029compositionUS RE467912.5y
FDA exclusivities (32)
Aug 30, 2031ODE-497Orphan Drug (7y)
Aug 30, 2031ODE-495Orphan Drug (7y)
Aug 30, 2031ODE-497Orphan Drug (7y)
Aug 30, 2031ODE-495Orphan Drug (7y)
Aug 30, 2031ODE-497Orphan Drug (7y)
Aug 30, 2031ODE-495Orphan Drug (7y)
Aug 30, 2031ODE-497Orphan Drug (7y)
Aug 30, 2031
comments(0)
5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
comments(0)
5-min edit window · permanent after that